BS
ALNY icon

Banco Santander’s Alnylam Pharmaceuticals ALNY Stock Holding History

Banco Santander’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-731
Closed -$291K – 472
2025
Q4 		$291K Buy
+731
New +$324K ﹤0.01% 407
2025
Q3 		– Sell
-1,245
Closed -$406K – 473
2025
Q2 		$406K Buy
+1,245
New +$345K ﹤0.01% 398
2022
Q2 		– Sell
-40,000
Closed -$6.53M – 369
2022
Q1 		$6.53M Buy
+40,000
New +$6.09M 0.07% 157
2020
Q3 		– Sell
-3,429
Closed -$508K – 352
2020
Q2 		$508K Buy
+3,429
New +$462K 0.01% 273

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Banco Santander's ALNY Position: Q1 2026 in Review

Banco Santander sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 731 shares — an estimated $291K sold.

Banco Santander first reported a position in ALNY in Q2 2020 and held it in 4 quarters. The position peaked at $6.53M in Q1 2022. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Banco Santander reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Banco Santander sold 731 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $291K.
  • Banco Santander first reported a position in Alnylam Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • Banco Santander's Alnylam Pharmaceuticals position peaked at $6.53M in Q1 2022.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Banco Santander's 13F filing for Q1 2026, filed 8 May 2026.